Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 3
2004 3
2005 8
2006 4
2007 13
2008 17
2009 15
2010 11
2011 18
2012 19
2013 17
2014 12
2015 18
2016 12
2017 9
2018 9
2019 11
2020 3
2021 2
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Moe SM, Patel UD, Silver J, Sun Y, Wang H, Chertow GM. Block GA, et al. JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468. JAMA. 2017. PMID: 28097356 Free article. Clinical Trial.
OBJECTIVE: To evaluate the relative efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, double-dummy active clinical trial was conducted comparing IV etelcalcetide vs …
OBJECTIVE: To evaluate the relative efficacy and safety of the IV calcimimetic etelcalcetide and the oral calcimimetic cinacalcet. DE …
Evaluating the clinical and mechanistic effects of eplerenone and amiloride monotherapy, and combination therapy with cinacalcet, in primary hyperparathyroidism: A placebo-controlled randomized trial.
Parksook WW, Heydarpour M, Brown JM, Turchin A, Mannstadt M, Vaidya A. Parksook WW, et al. Clin Endocrinol (Oxf). 2023 Apr;98(4):516-526. doi: 10.1111/cen.14840. Epub 2022 Nov 8. Clin Endocrinol (Oxf). 2023. PMID: 36316798 Free PMC article. Clinical Trial.
We also investigated the synergistic effect of these interventions when combined with cinacalcet for an additional 2 weeks. DESIGN: Randomized, double-blinded, three parallel-group, placebo-controlled trial. ...Both eplerenone and amiloride therapy induced significant redu …
We also investigated the synergistic effect of these interventions when combined with cinacalcet for an additional 2 weeks. DESIGN: R …
Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Leere JS, Karmisholt J, Robaczyk M, Lykkeboe S, Handberg A, Steinkohl E, Brøndum Frøkjær J, Vestergaard P. Leere JS, et al. Lancet Diabetes Endocrinol. 2020 May;8(5):407-417. doi: 10.1016/S2213-8587(20)30063-2. Lancet Diabetes Endocrinol. 2020. PMID: 32333877 Clinical Trial.
Patients were assigned (1:1:1) via permuted block randomisation to receive 30 mg cinacalcet per day plus 60 mg denosumab subcutaneously every 6 months (n=14; combination group) for 1 year, denosumab plus placebo (n=16; denosumab group) for 1 year, or placebo plus placebo i …
Patients were assigned (1:1:1) via permuted block randomisation to receive 30 mg cinacalcet per day plus 60 mg denosumab subcutaneous …
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
Chang TI, Abdalla S, London GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Dehmel B, Goodman WG, Chertow GM. Chang TI, et al. J Hum Hypertens. 2016 Mar;30(3):204-9. doi: 10.1038/jhh.2015.56. Epub 2015 Jun 4. J Hum Hypertens. 2016. PMID: 26040438 Clinical Trial.
We conducted a secondary analysis of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, in which patients receiving hemodialysis with sHPT were randomly assigned to receive cinacalcet or placebo. We sought to examine wh …
We conducted a secondary analysis of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial …
Parathyroidectomy versus oral cinacalcet on cardiovascular parameters in peritoneal dialysis patients with advanced secondary hyperparathyroidism (PROCEED): a randomized trial.
Wang AY, Lo WK, Cheung SC, Tang TK, Yau YY, Lang BH. Wang AY, et al. Nephrol Dial Transplant. 2023 Jul 31;38(8):1823-1835. doi: 10.1093/ndt/gfad043. Nephrol Dial Transplant. 2023. PMID: 36869794 Clinical Trial.
With the same monitoring frequency, cinacalcet-treated patients had fewer hospitalizations due to hypercalcemia (1.8%) than patients who underwent PTx (16.7%) (P = .005). ...Cinacalcet may be used in place of PTx for treating advanced SHPT. Long-term and powered stu …
With the same monitoring frequency, cinacalcet-treated patients had fewer hospitalizations due to hypercalcemia (1.8%) than patients …
Pharmacokinetics and pharmacodynamics of cinacalcet in patients with renal failure receiving hemodialysis and hemodiafiltration therapy.
Shi W, Tan X, Li Z, Zhang M, Huang B, Lu F, Jia J, Chen J, Zhong M. Shi W, et al. Int J Clin Pharmacol Ther. 2019 Jun;57(6):284-289. doi: 10.5414/CP203260. Int J Clin Pharmacol Ther. 2019. PMID: 30935461 Clinical Trial.
OBJECTIVE: Few studies have focused on the effects of dialysis on cinacalcet. In addition, there is no data available on hemodiafiltration (HDF) all over the world. ...Considering the high protein binding rate of cinacalcet, this may lead to the great free-drug clea …
OBJECTIVE: Few studies have focused on the effects of dialysis on cinacalcet. In addition, there is no data available on hemodiafiltr …
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Dehmel B, Trotman ML, Modafferi DM, Goodman WG. Parfrey PS, et al. J Clin Endocrinol Metab. 2013 Dec;98(12):4834-44. doi: 10.1210/jc.2013-2975. Epub 2013 Oct 9. J Clin Endocrinol Metab. 2013. PMID: 24108314 Clinical Trial.
MAIN OUTCOME MEASURES: Outcomes included PTX; severe, unremitting HPT; and use of commercial cinacalcet (a protocol violation). INTERVENTION: Intervention was cinacalcet (30-180 mg daily) or placebo for up to 64 months. ...CONCLUSIONS: Severe unremitting HPT develop …
MAIN OUTCOME MEASURES: Outcomes included PTX; severe, unremitting HPT; and use of commercial cinacalcet (a protocol violation). INTER …
A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism.
Eddington H, Chinnadurai R, Alderson H, Ibrahim ST, Chrysochou C, Green D, Erekosima I, Hutchison A, Bubtana A, Hegarty J, Kalra PA. Eddington H, et al. BMC Nephrol. 2021 Mar 23;22(1):106. doi: 10.1186/s12882-021-02312-2. BMC Nephrol. 2021. PMID: 33757437 Free PMC article. Clinical Trial.
BACKGROUND: Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardiovascular health with improved parathormone (PTH) and phosphate control. ...RESULTS: There was no evidence of a group difference in the prog …
BACKGROUND: Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardi …
Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study.
Asada S, Yoshida K, Fukuma S, Nomura T, Wada M, Onishi Y, Kurita N, Fukagawa M, Fukuhara S, Akizawa T. Asada S, et al. PLoS One. 2019 May 29;14(5):e0216399. doi: 10.1371/journal.pone.0216399. eCollection 2019. PLoS One. 2019. PMID: 31141505 Free PMC article. Clinical Trial.
OBJECTIVES: To elucidate the effect of cinacalcet use on all-cause and cause-specific hospitalization outcomes using a prospective cohort of maintenance hemodialysis patients. ...CONCLUSIONS: Cinacalcet initiation in patients on maintenance hemodialysis had no effec …
OBJECTIVES: To elucidate the effect of cinacalcet use on all-cause and cause-specific hospitalization outcomes using a prospective co …
Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.
Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P. Floege J, et al. Kidney Int. 2018 Jun;93(6):1475-1482. doi: 10.1016/j.kint.2017.12.014. Epub 2018 Mar 7. Kidney Int. 2018. PMID: 29525393 Free article. Clinical Trial.
At least one episode of hypocalcemia developed within 16 weeks after the first administered dose among 58.3% of 1938 patients randomized to cinacalcet versus 14.9% of 1923 patients randomized to placebo. Hypocalcemia in the cinacalcet group was severe in 18.4% of th …
At least one episode of hypocalcemia developed within 16 weeks after the first administered dose among 58.3% of 1938 patients randomized to …
176 results